Frankfurt - Delayed Quote EUR

BioXcel Therapeutics, Inc. (BX2.F)

Compare
0.3673
+0.0010
+(0.27%)
At close: January 10 at 6:41:46 PM GMT+1

Research Analysis

Revenue vs. Earnings

Revenue 214k
Earnings -13.65M
Q4'23
Q1'24
Q2'24
Q3'24
-25M
-20M
-15M
-10M
-5M
0
 

Analyst Price Targets

Earnings Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts --------
Avg. Estimate 0000
Low Estimate 0000
High Estimate 0000
Year Ago EPS --------

Revenue Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts 5155
Avg. Estimate 936.26k400k3.26M5.99M
Low Estimate 298.36k400k2.2M1.5M
High Estimate 2.34M400k5.37M14.17M
Year Ago Sales 376k582k1.38M3.26M
Sales Growth (year/est) 149.01%-31.27%136.11%83.97%

EPS Trend

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Current Estimate 0000
7 Days Ago 0000
30 Days Ago 0000
60 Days Ago 0000
90 Days Ago 0000

EPS Revisions

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
BX2.F --------
S&P 500 8.66%11.51%14.05%13.39%

Upgrades & Downgrades

Downgrade B of A Securities: Buy to Underperform 1/7/2025
Maintains Canaccord Genuity: Buy to Buy 1/6/2025
Maintains HC Wainwright & Co.: Buy to Buy 10/21/2024
Reiterates HC Wainwright & Co.: Buy to Buy 9/6/2024
Maintains Canaccord Genuity: Buy to Buy 8/30/2024
Maintains UBS: Neutral to Neutral 8/9/2024

Related Tickers